Medicare beneficiaries who rely on Ozempic for diabetes management will pay sharply less starting January 1, 2027, when a federally negotiated price of $274 per month replaces the drug’s current list price of $959. The Centers for Medicare and Medicaid Services completed its second round of Inflation Reduction Act drug price negotiations, setting Maximum Fair Prices for 15 drugs that include three semaglutide products: Ozempic, Rybelsus, and Wegovy. The price cut, roughly 71 percent off the list price, represents one of the largest single reductions to emerge from the program so far.
How the $274 Ozempic price reshapes Part D plan math
The new Maximum Fair Price does not take effect for another seven months, but its impact on Medicare Part D plan design is already in motion. Plan sponsors that submit bids for the 2027 coverage year can now model the statutory price ceiling into their formulary decisions. Because the $274 figure is locked in by federal negotiation rather than subject to manufacturer rebate negotiations, plans gain a degree of cost certainty they do not have with competing GLP-1 drugs that were not selected for the program.
That dynamic could accelerate Ozempic’s formulary placement relative to non-negotiated GLP-1 alternatives. A plan building its 2027 benefit structure knows the maximum it will pay for Ozempic, which simplifies actuarial projections and may lead sponsors to favor it over rival injections whose net prices remain variable. The same logic applies to Rybelsus and Wegovy, both of which received their own Maximum Fair Prices as part of the second negotiation cycle. For beneficiaries, that could translate into more consistent coverage policies, fewer prior authorization hurdles, and a clearer sense of monthly pharmacy costs once plan formularies are finalized.
A separate federal program adds another layer of timing complexity. The Medicare GLP-1 Bridge demonstration launches July 1, 2026, offering interim pricing arrangements for semaglutide products before the negotiated prices kick in. CMS has clarified that the Bridge program and the IRA-negotiated Maximum Fair Price operate on distinct timelines, with the negotiated rate activating only on January 1, 2027. Plans will have to account for this handoff when they design benefits that span the second half of 2026 and the full 2027 plan year, particularly for patients who initiate therapy under the Bridge and remain on treatment once the lower negotiated prices apply.
CMS price files and the drugs on the negotiation list
The $274 monthly figure for Ozempic appears in downloadable datasets CMS published on its negotiated prices page, which hosts machine-readable files and drug-specific explanation documents. The agency’s data ties the price to the semaglutide injection identified by NDC 0169-4130-13, a product code confirmed in the FDA-approved labeling for Ozempic. Similar tables list the negotiated amounts for oral semaglutide (Rybelsus) and higher-dose semaglutide for chronic weight management (Wegovy), making clear that the price changes extend beyond a single formulation.
All 15 drugs selected for this round treat conditions ranging from cancer to chronic metabolic disease. According to a federal announcement, the group includes widely used therapies for heart failure, autoimmune disorders, and blood cancers that collectively account for billions in annual Medicare spending. CMS framed the negotiations as a direct mechanism to lower Part D spending while preserving access for seniors. The agency’s materials emphasize that the Maximum Fair Prices are benchmarked against current net spending and statutory discounts, but they do not provide drug-by-drug projections of how many patients will use each product in 2027.
The selection of three semaglutide products in a single round is notable because it signals federal pricing pressure across an entire drug class rather than isolated agents. By targeting both injectable and oral semaglutide, CMS effectively set reference points that Part D plans can use when comparing other GLP-1s that were not negotiated in this cycle. Manufacturers of competing drugs may respond with steeper rebates or alternative contracting strategies to avoid losing market share to a product whose ceiling price is now publicly known.
What the negotiated prices mean for beneficiaries
For individual Medicare enrollees, the negotiated Ozempic price does not automatically translate into a $274 copay. Out-of-pocket costs will still depend on each plan’s benefit design, including tier placement, coinsurance rates, and whether the beneficiary has reached the annual Part D out-of-pocket threshold. However, because the Maximum Fair Price caps what plans and their pharmacy benefit managers pay, it narrows the range of possible patient charges and reduces the likelihood that list-price inflation will drive sudden spikes in cost sharing.
CMS has highlighted that, taken together, the 15 negotiated drugs are expected to generate substantial savings for the Medicare program and its enrollees compared with 2024 spending levels, though the agency has not yet released detailed per-patient estimates. In its press materials, the agency stresses that negotiated prices must be reflected in Part D formularies and that plans cannot charge beneficiaries more than the statutory share of the Maximum Fair Price.
Between the GLP-1 Bridge demonstration in mid-2026 and the formal start of negotiated pricing in early 2027, Medicare beneficiaries using Ozempic, Rybelsus, or Wegovy should see a gradual but significant reduction in the cost of semaglutide therapy. The precise savings will vary by plan and by patient, yet the presence of a clear federal ceiling gives both actuaries and enrollees a firmer basis for anticipating what these drugs will cost in the years ahead.
